Journal of Health Economics and Outcomes Research, published by COLUMBIA DATA ANALYTICS, LLC, serves as a vital resource in the field of health policy and public health, providing researchers, professionals, and students with open access to pioneering studies since its inception in 2013. With its ISSN and E-ISSN both listed as 2327-2236, this journal aims to disseminate high-quality research that evaluates healthcare efficiency and outcomes. Situated in the United States, at 145 Hudson St., Suite 205, New York, NJ 10013, it has made significant strides in its category quartiles within the 2023 rankings, achieving Q2 status in both Health Policy and Public Health, Environmental and Occupational Health. Furthermore, it maintains respectable Scopus rankings, with a percentile of 51st in health policy and 49th in public health. By bridging gaps in health economics and policy discourse, the journal stands as an indispensable platform for advancing knowledge and fostering innovation in health services research.

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.

Pharmacy is a premier open-access journal published by MDPI, dedicated to advancing research in the dynamic field of pharmaceutical sciences. Since its inception in 2013, this journal has become a vital platform for disseminating novel findings, reviews, and insights related to drug development, pharmacokinetics, pharmaceutical technology, and clinical applications. With an E-ISSN of 2226-4787, Pharmacy prioritizes accessibility and visibility, allowing researchers, professionals, and students from around the globe to engage with cutting-edge research without barriers. The journal plays a crucial role in shaping pharmaceutical education and practice, fostering innovative ideas and collaborative approaches aimed at improving health outcomes. As part of the MDPI family, Pharmacy is committed to maintaining high-quality standards, ensuring that all published articles undergo rigorous peer review.

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

JOURNAL OF PHARMACY PRACTICE, published by SAGE PUBLICATIONS INC, is a vital resource for researchers, pharmacy practitioners, and students dedicated to advancing the pharmacological and pharmaceutical sciences. Established in 1988, the journal serves as a platform for original research, reviews, and critical analyses in the fields of pharmacy and pharmacology. With an impressive impact factor and a strong presence in the Q2 category in Pharmacy and Q3 in Pharmacology (medical) as of 2023, it reflects the journal's commitment to delivering high-quality scholarly content that addresses pressing issues in pharmacy practice and medication management. The journal is indexed in Scopus, ranking #154 out of 272 in the field of Medicine and Pharmacology, positioning it within the 43rd percentile. Although it currently does not offer open access options, it remains an essential publication for those seeking to stay updated on innovations and best practices in the pharmacy sector, making it an indispensable tool for academic and professional growth.

American Health and Drug Benefits, published by ENGAGE HEALTHCARE COMMUNICATIONS INC, is a pivotal journal dedicated to advancing the understanding of health policy and management in the pharmaceutical sector. Launched in 2009, this journal serves as a vital resource for researchers, practitioners, and policymakers engaged in the dynamic interplay between health care quality, drug accessibility, and effective management strategies. With its ISSN 1942-2962 and E-ISSN 1942-2970, the journal has established itself within the community, evidenced by its 2023 Scopus rankings, including Q4 in Health Policy and Q3 in Strategy and Management. Although currently lacking an open-access model, American Health and Drug Benefits remains a crucial platform for disseminating high-quality research that informs health care delivery and policy decisions in the United States. Its commitment to rigorous scholarship contributes to better health outcomes and fosters innovation in drug benefits management.

Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz, an esteemed journal published by Springer, stands at the forefront of research in the realm of public health, environmental health, and occupational safety. With a commendable Q2 ranking in the 2023 Category Quartiles and a Scopus rank of #303 out of 665 in its field, this journal provides a significant platform for the dissemination of high-quality research. The journal focuses on a broad spectrum of health-related topics, aiming to bridge the gap between research and practice, thereby enhancing public health policies and interventions. While it operates under a traditional subscription model, readers can access a plethora of cutting-edge studies that contribute to the ongoing dialogue surrounding global health challenges. With its foundation dating back to 1999, Bundesgesundheitsblatt is dedicated to fostering professional growth and education within the health community, making it an invaluable resource for researchers, practitioners, and students alike.

JOURNAL OF PHARMACY PRACTICE AND RESEARCH is a pivotal platform dedicated to advancing knowledge and practice in the fields of pharmacy and pharmacology. Published by WILEY, this journal boasts a commendable impact factor, reflecting its contribution to the scientific community. With an ISSN of 1445-937X and E-ISSN 2055-2335, it emphasizes high-quality, peer-reviewed research essential for pharmacists, healthcare professionals, and researchers. Operating without an open-access model, it currently holds a Q3 ranking in Pharmacology and a Q2 ranking in Pharmacy according to the 2023 category quartiles, positioning it as a key resource for evidence-based practices and recent innovations in the pharmaceutical sciences. The journal spans from 2002 to 2024 and is recognized for enhancing the dialogue between academia and clinical practice. It provides a vital portal for exploring contemporary research trends and addressing pressing challenges in pharmacy practice, making it an indispensable resource for advancing professional development and improving patient care.

Annales Pharmaceutiques Francaises, an esteemed journal published by MASSON EDITEUR, serves as a pivotal platform in the field of Pharmaceutical Science and Pharmacology. Established in 1945 and continuing through 2024, this journal showcases significant contributions to the advancement of pharmaceutical sciences, bridging the gap between research, development, and practical applications. Although it currently does not offer open access, its established reputation and Q3 ranking in both Pharmaceutical Science and Pharmacology highlight its role in disseminating impactful studies. With an ISSN of 0003-4509, the journal is indexed in Scopus, boasting a respectable percentile ranking for both domains, and remains a vital resource for researchers, professionals, and students dedicated to exploring the latest advancements in the pharmaceutical field. Based in France, at 21 Street Camille Desmoulins, Issy, 92789 Moulinais Cedex 9, it aims to foster a deeper understanding of pharmacological innovations and therapeutic agents among its diverse readership.